Ute von Wangenheim

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial

T. Maher, L. Hummers, O. Distler, 2020, Annals of the Rheumatic Diseases.

Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.

G. Scagliotti, N. Pavlakis, T. Nakano, 2019, The Lancet. Respiratory medicine.

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.

M. Socinski, G. Scagliotti, S. Novello, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.

G. Scagliotti, T. Nakano, J. V. van Meerbeeck, 2017, Clinical lung cancer.

A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3).

R. Kaiser, A. Dingemans, A. Hackshaw, 2018, Lung cancer.

Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects

Claudia Dallinger, A. Jungnik, K. Marzin, 2018, European Journal of Drug Metabolism and Pharmacokinetics.

Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

N. Schmitz, G. Lenz, R. Bouabdallah, 2020, Investigational New Drugs.

Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects

Claudia Dallinger, K. Marzin, D. Luedtke, 2018, European Journal of Drug Metabolism and Pharmacokinetics.

SPS-7Nintedanib plus pemetrexed/cisplatin in patients with MPM: Phase II findings from the placebo-controlled LUME-Meso trial

G. Scagliotti, S. Novello, F. Grosso, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.